	US 12,472,232 B2
	Methods to treat viral infections
Jeffrey S. Glenn, Stanford, CA (US); Edward A. Pham, Palo Alto, CA (US); and Anming Xiong, Redwood City, CA (US)
Assigned to The Board of Trustees of the Leland Stanford Junior University, Stanford, CA (US)
Appl. No. 17/617,267
Filed by The Board of Trustees of the Leland Stanford Junior University, Stanford, CA (US)
PCT Filed Jun. 9, 2020, PCT No. PCT/US2020/036805 § 371(c)(1), (2) Date Dec. 7, 2021, PCT Pub. No. WO2020/251941, PCT Pub. Date Dec. 17, 2020.
Claims priority of provisional application 62/860,533, filed on Jun. 12, 2019.
Prior Publication US 2022/0347263 A1, Nov. 3, 2022
Int. Cl. A61K 38/00 (2006.01); A61K 38/17 (2006.01); A61K 38/21 (2006.01); A61P 31/20 (2006.01)

CPC A61K 38/177 (2013.01) [A61K 38/21 (2013.01); A61P 31/20 (2018.01)]

19 Claims

1. A method of reducing hepatitis virus in an individual, the method comprising:

contacting the individual with a therapeutically effective dose of an antibody that specifically binds to CD24 and blocks binding activity of CD24 in a dose sufficient to kill hepatovirus infected cells without unacceptable toxicity, for a period of time sufficient to reduce the amount of hepatitis virus in the individual.